Details

Autor(en) / Beteiligte

• Ognibene, Marzia
• Scala, Marcello
• Iacomino, Michele
• Schiavetti, Irene
• Madia, Francesca
• Traverso, Monica
• Guerrisi, Sara
• Di Duca, Marco
• Caroli, Francesco
• Baldassari, Simona
• Tappino, Barbara
• Romano, Ferruccio
• Uva, Paolo
• Vozzi, Diego
• Chelleri, Cristina
• Piatelli, Gianluca
• Diana, Maria Cristina
• Zara, Federico
• Capra, Valeria
• Pavanello, Marco
• De Marco, Patrizia

Titel

Moyamoya Vasculopathy in Neurofibromatosis Type 1 Pediatric Patients: The Role of Rare Variants of RNF213

Ist Teil von

• Cancers, 2023-03, Vol.15 (6), p.1916

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder caused by mutations in gene, coding for neurofibromin 1. NF1 can be associated with Moyamoya disease (MMD), and this association, typical of paediatric patients, is referred to as Moyamoya syndrome (MMS). MMD is a cerebral arteriopathy characterized by the occlusion of intracranial arteries and collateral vessel formation, which increase the risk of ischemic and hemorrhagic events. gene mutations have been associated with MMD, so we investigated whether rare variants of could act as genetic modifiers of MMS phenotype in a pediatric cohort of 20 MMS children, 25 children affected by isolated MMD and 47 affected only by isolated NF1. By next-generation re-sequencing (NGS) of patients' DNA and gene burden tests, we found that seems to play a role only for MMD occurrence, while it does not appear to be involved in the increased risk of Moyamoya for MMS patients. We postulated that the loss of neurofibromin 1 can be enough for the excessive proliferation of vascular smooth muscle cells, causing Moyamoya arteriopathy associated with NF1. Further studies will be crucial to support these findings and to elucidate the possible role of other genes, enhancing our knowledge about pathogenesis and treatment of MMS.